Eisai's Alzheimer's Drug Leqembi Grows 27% as Quarterly Profit Jumps 26%
Lenvima, Leqembi and Dayvigo again did the heavy lifting for Eisai's first quarter, with Leqembi's Americas sales up 71% masking a China pullback tied to last year's distributor stocking, while the drugmaker left its full-year targets exactly where it set them in May.